Raúl Rincón

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7456595/publications.pdf

Version: 2024-02-01

21 534 11 21 papers citations h-index g-index

21 21 21 1112 all docs docs citations times ranked citing authors

| # | Article | IF | Citations |
|----|--|-----|-----------|
| 1 | Comprehensive Plasma Metabolomic Profile of Patients with Advanced Neuroendocrine Tumors (NETs). Diagnostic and Biological Relevance. Cancers, 2021, 13, 2634. | 3.7 | 9 |
| 2 | UNR/CSDE1 Expression Is Critical to Maintain Invasive Phenotype of Colorectal Cancer through Regulation of c-MYC and Epithelial-to-Mesenchymal Transition. Journal of Clinical Medicine, 2019, 8, 560. | 2.4 | 25 |
| 3 | Combination of KIR2DS4 and Fcî ³ RIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. Scientific Reports, 2019, 9, 2589. | 3.3 | 9 |
| 4 | Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals. Scientific Reports, 2018, 8, 4802. | 3.3 | 8 |
| 5 | A comprehensive study of calcific aortic stenosis: from rabbit to human samples. DMM Disease Models and Mechanisms, $2018,11,.$ | 2.4 | 6 |
| 6 | Recent advances and clinical insights into the use of proteomics in the study of atherosclerosis. Expert Review of Proteomics, 2017, 14, 701-713. | 3.0 | 6 |
| 7 | Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer. Oncotarget, 2017, 8, 40169-40180. | 1.8 | 20 |
| 8 | c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer. Molecular Cancer Therapeutics, 2016, 15, 2780-2790. | 4.1 | 13 |
| 9 | Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma. International Journal of Molecular Sciences, 2015, 16, 19447-19457. | 4.1 | 3 |
| 10 | Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer. Oncotarget, 2015, 6, 5903-5917. | 1.8 | 35 |
| 11 | Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2015, 21, 347-356. | 7.0 | 63 |
| 12 | PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. Oncotarget, 2015, 6, 4299-4314. | 1.8 | 87 |
| 13 | PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential. Molecular Cancer Therapeutics, 2014, 13, 938-947. | 4.1 | 109 |
| 14 | Re: Role of Oncogenic K-Ras in Cancer Stem Cell Activation by Aberrant Wnt/Â-Catenin Signaling. Journal of the National Cancer Institute, 2014, 106, dju196-dju196. | 6.3 | 1 |
| 15 | Up-regulation of c-Cbl suggests its potential role as oncogene in primary colorectal cancer. International Journal of Colorectal Disease, 2014, 29, 641-641. | 2.2 | 7 |
| 16 | Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy. British Journal of Cancer, 2014, 110, 2700-2707. | 6.4 | 23 |
| 17 | Deregulation of miR-200b, miR-200c and miR-429 indicates its potential relevant role in patients with colorectal cancer liver metastasis. Journal of Surgical Oncology, 2014, 110, 484-485. | 1.7 | 22 |
| 18 | Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer. British Journal of Cancer, 2014, 111, 756-762. | 6.4 | 17 |

| # | Article | lF | CITATIONS |
|----|--|-----|-----------|
| 19 | Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1823-1829. | 3.8 | 34 |
| 20 | Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1249-1250. | 2.5 | 1 |
| 21 | Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer. Oncotarget, 2014, 5, 196-210. | 1.8 | 36 |